Pharmaceuticals, Biotechnology and Life Sciences
Moderna has made a deal with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.
Pfizer and BioNTech said that the FDA is expected to make a decision on Emergency Use Authorization in the coming days after giving a positive vote based on totality of scientific evidence presented by the companies, including Phase 3 efficacy and safety data, which would make BNT162b2 the first COVID-19 vaccine available in the U.S.
Today BIOTECH AUSTRIA, the first specific branch association for the biotechnology industry in Austria was founded. The founding members include numerous companies and institutions of Austrian biotechnology. The foundation of the association arises from an initiative by board members of APEIRON Biologics AG, Haplogen Bioscience GmbH, Hookipa Pharma GmbH and Lexogen GmbH.
HALIX B.V. has signed an agreement with AstraZeneca AB for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine.
SeraNovoa pharmaceutical company with a breakthrough proprietary formulation platform for enhancing drug bioavailability has appointed Dr Michiel Van Speybroeck to the role of Chief Development Officer (CDO) with immediate effect.
Actinium Pharmaceuticals has reported 67% overall response rate in first cohort in Actimab-A Venetoclax combination trial in relapsed and refractory AML at ASH, which includes one complete response in patient with TP53 mutation and one partial response reported in patients with poor risk adverse cytogenetics with subtherapeutic dose of Actimab-A indicative of mechanistic synergy with venetoclax.
Osteolab has completed a second financing round in the amount of approximately €1.6 million. The funds were provided by Seed and Start-Up Fonds II of MBG (Mittelständische Beteiligungsgesellschaft) Kiel, Labor Dr. Krause & Kollegen MVZ GmbH, Kiel, and SVM Verwaltungsgesellschaft mbH, Hamburg, as new shareholders.
German independent research institute Biomed X announces has completed its first joint research project with Boehringer Ingelheim in the fields of neuroscience. The results of the project are transferred to Boehringer Ingelheim for further development.
Piramal Pharma Solutions has said it plans to expand its facility in Riverview, Michigan, for which it will invest approximately $32 Million to add capacity and new capabilities in potent and non-potent API development and manufacturing.
Immunicum AB has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the Company’s lead…